Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18105811 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL13430947 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL19327387 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL2933537 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL13917736 | 0.95 | PDE4A (0.58) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL13917735 | 0.95 | PDE4A (0.58) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL769787 | 0.95 | PDE4A (0.58) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL4344384 | 0.92 | TDP1 (0.60) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL18586001 | 0.92 | TDP1 (0.60) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL1650142 | 0.92 | TDP1 (0.60) | PDE4ALMNAL3MBTL1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020161747-A1 | OSTEOBLAST CELL-MIXTURE, AND IMPLEMENTATIONS THEREOF | REGROW BIOSCIENCES PRIVATE LIMITED (IN) | 2020-08-13 | — | — | WO | claimed |
| EP-0719846-B1 | Ink composition and process for producing the same | SEIKO EPSON CORP (JP) | 2003-03-19 | — | — | EP | claimed |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | THE BROAD INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250376656-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-12-11 | — | — | US | disclosed |
| CN-119932002-A | Double-function endo algin lyase and coding gene and application thereof | 山东第二医科大学 | 2025-05-06 | — | — | CN | disclosed |
| US-20240156877-A1 | COMPOSITIONS AND USES THEREFOR | MELCARE MEDICAL PTY LTD (AU) | 2024-05-16 | — | — | US | disclosed |
| EP-4368178-A1 | COMPOSITIONS OF HONEY AND GLUCONIC ACID AND USES THEREFOR | Melcare Medical Pty Ltd (AU) | 2024-05-15 | — | — | EP | disclosed |
| CN-118001410-A | Composition and use thereof | 麦尔凯亚医学股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023240046-A2 | MULTI-OMICS ASSESSMENT | PrognomIQ, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11746355-B2 | Controlling fungal pathogens using RNAi-based strategy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-05 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| EP-0719846-A2 | Ink composition and process for producing the same | SEIKO EPSON CORPORATION (JP) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| US-5336588-A | Containing monosaccharide preservative; solubility, storage stability | KONICA CORPORATION (JP) | 1994-08-09 | — | — | US | disclosed |
| EP-0589624-A1 | Solid photographic color developing composition for silver halide color photographic light-sensitive material | KONICA CORPORATION (JP) | 1994-03-30 | — | — | EP | disclosed |
| EP-0547796-A1 | Solid chemicals for processing silver halide photographic light-sensitive material | KONICA CORPORATION (JP) | 1993-06-23 | — | — | EP | disclosed |
| EP-0329481-A2 | Anchimeric radiometal chelating compounds | NEORX CORPORATION (US) | 1989-08-23 | — | — | EP | disclosed |
| US-4448912-A | QUATERNIZATION WITH PRIMARY AND/OR SECONDARY AMINE AND ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-05-15 | — | — | US | disclosed |
| EP-0058942-A1 | Thermosettable binders based on an aqueous dispersion of a solid epoxy resin, method for their preparation and their application | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | STUB1, SAMM50, CD14 | PDE4A 1038/4885LMNA 2887/4885L3MBTL1 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.